Advances and Challenges in the control of Chagas disease Chris Schofield, London School of Hygiene and Tropical Medicine, UK

Rationale and desing of a proof-of-concept Phase II clinical study of E1224, a new drug candidate for chronic Chagas disease Faustino Torrico, University of San Simon, Bolivia

African trypanosomiasis: current burden of disease and geographical distribution Pere Simarro, World Health Organization, Switzerland

African trypanosomiasis: neurological aspects Marina Bentivoglio, University of Verona, Italy

Oral communications:

• T1.3 P8-01
  A Multicenter, open label, phase III study of therapeutic use of the co-administration of nifurtimox and eflornithine (NECT) for Human African Trypanosomiasis (NECT FIELD): safety profile in children during initial hospitalization
  Olaf Valverde Mordt, Caecilia Schmid, Victor Kande, Wilfried Mutombo, Médard Ilunga, Ismael Lumpungu, Sylvain Mutanda, Digas Tete, Pathou Nganzobo, Nono Mubwa, Mays Kisala, Johannes Blum, Séverinne Blésson, Nathalie Strub Wourgaft


• T1.3 P8-02
  Effectiveness of short vs. long treatment schedules with pentamidine in first-stage HAT, a large field cohort study
  Sophie Bastide, Gerardo Priotto, René Ecochard, Jean-François Etard